Exxe Group Selects PCG Advisory Group for Investor Relations and Strategic Communications
NEW YORK, NY, June 13, 2018 (GLOBE NEWSWIRE) -- Exxe Group
(OTC PINK: AXXA), a diversified company focused on
acquisitions in the real estate, technology, media, and
financial services sectors, today announced that it has
retained PCG Advisory Group, a leading investor relations and
digital strategies firm, to serve as an advisor for investor
relations and strategic communications.
“With Exxe’s change in management and corporate strategy, it was important to engage with an advisor who understands what we’re working to build and how to best position and introduce that investment case to investors. PCG’s seasoned team of senior advisors has the experience and contacts to assist us with adopting best practices and implementing strategies to raise Exxe’s visibility and awareness with the investment community,” said Eduard Nazmeev, Head of European Business Development at Exxe Group.
“We’re pleased to work with Exxe Group as they roll out their strategy to build a company with diverse assets. PCG has a long history of working with emerging growth companies and we look forward to using our expertise to assist Exxe Group in achieving their goals,” said Jeff Ramson, Founder and CEO of PCG Advisory Group.
About Exxe Group:
Exxe Group is a diversified corporation focusing on acquisitions in the following sectors: real estate and technology with an emphasis on fintech, media, and financial services. We are an acquisition-driven company. Our strategy is to acquire controlling equity interests in undervalued companies and then take an active role in improving their performance - accelerating their growth by providing them with both access to capital and management expertise. For additional information go to: www.axxar.io
About PCG Advisory Group
Founded in 2008, PCG Advisory is dedicated to the delivery of top-tier strategic advisory services that encompass investor and stakeholder relations, capital markets navigation, corporate communications and social media management for emerging growth companies. The team at PCG has extensive experience with life science, fintech and blockchain technology and works with innovative and emerging companies from around the globe. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail and institutional investors and stakeholders in its proprietary and extensive distribution network, and through the use of unique digital marketing and audience development techniques. For more information, go to: www.pcgadvisory.com
Forward Looking Statement:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release.
Contact: Exxe Group P: 855-285-2285 E: email@example.com Stephanie Prince PCG Advisory Group P: 646-762-4518 firstname.lastname@example.org
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
- Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types
- Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress
- DGAP-News: MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference
- Elbit Systems Announces the Results of its Extraordinary and Annual General Meeting of Shareholders Held on October 18, 2018
- Varian Forms FlashForward Consortium to Study Ultra-high Dose Rate Cancer Treatments with Protons
- Varian Introduces New ProBeam 360° Proton Therapy System